ClinicalTrials.gg
RecruitingNCT05789758Updated Nov 12, 2026

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

An observational study in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 14 sites in 2 countries. Open to female participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Biogen · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 12, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 54 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Started
2023
with 1 other
Observational
5 of 27
1 open now
Registered
23rd of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is one of 2 that started in 2023, is one of 5 observational ones, and was the 23rd registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 54 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people with SMA may now reach the age where they can become pregnant. But, there is not enough information known yet about what the effects of nusinersen may be on pregnant people with SMA or on their babies.

This is known as an "observational" study, which collects health information about study participants without changing their medical care. The pregnant participants for this study will be found using 3 different groups of SMA study research centers:

  • ISMAR-US (International SMA Registry in the United States)
  • UK Adult SMA-REACH (Adult SMA Research and Clinical Hub in the United Kingdom)
  • SMArtCARE (Austria, Germany, and Switzerland)
  • Polish SMA Patient Registry

The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:

  • Those who received nusinersen up to 14 months before the first day of their last period before getting pregnant. This was either the standard dose of 12 milligrams (mg) of nusinersen or the higher dose (50/28 mg).
  • Those who received nusinersen 14.5 months before the day they got pregnant
  • Those who received 12 mg or 50/28 mg of nusinersen during any time in their pregnancy

The main questions researchers want to learn about in this study are:

  • Loss of pregnancy overall
  • Loss of pregnancy before the baby was 20 weeks old
  • Loss of pregnancy after the baby becomes 20 weeks old
  • Live births
  • Loss of the baby after birth
  • Babies who have problems in their body that develop during pregnancy
  • Babies who are small for their age while in the participant's uterus
  • Pregnancy that happens outside of the uterus
  • How many participants die during pregnancy, while the baby is being born, and up to 12 weeks after delivering the baby
  • Babies who develop problems in their body after birth

Researchers will also compare this information to people without SMA who have not received nusinersen.

This study will be done as follows:

  • Information will start being collected when the participant decides to join the study.
  • Participants will be contacted at each trimester (about every 3 months) to learn about their health and pregnancy.
  • Participants' doctors will be contacted at each trimester, when the participants are about 6 or 7 months pregnant, and about 4 weeks after the delivery of the baby.
  • The babies' doctors will be contacted when the baby is 1, 2, 6, 12, 18, and 24 months old.
  • Each participant will be in the study until the end of their pregnancy and for up to 12 weeks after delivery. Each baby will be in the study for up to 2 years after birth.
  • The study overall will last at least 10 years from when the first participant joins the study.
Read the detailed description

The primary objectives of the study are to prospectively evaluate pregnancy complications and outcomes in participants with SMA, birth outcomes and adverse effects in infants born to participants with SMA, who were exposed to nusinersen 12 or 50/28 milligrams (mg) up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before the date of conception, and/or at any time during their pregnancy. The secondary objective of the study is to evaluate pregnancy outcomes in participants with SMA exposed to nusinersen 12 or 50/28 mg as compared with participants without SMA who were not exposed to nusinersen (e.g., participants from external, general population comparators).

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 54 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant participants with SMA who are exposed to nusinersen from the UK Adult SMA REACH, ISMAR - US, SMArtCARE, and Polish SMA Patient registries will be enrolled to obtain information on effects of nusinersen on pregnancy complications and outcomes.

Eligibility criteria

Key Inclusion Criteria:

  • Participant who is currently pregnant (or was pregnant during the relevant exposure window) and enrolled in the United States (US) network of the ISMAR registry, the United Kingdom (UK) Adult SMA REACH, the Germany, Austria, Switzerland network of the SMArtCARE registry, or the Polish SMA Patient registry.
  • Genetic documentation of spinal muscular atrophy linked to chromosome 5q (5q SMA).
  • Documentation that the participant was exposed to nusinersen 12 or 50/28 mg up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before conception, and/or at any time during their pregnancy.

Key Exclusion Criteria:

  • Treatment with risdiplam at any time from the first day of their LMP, 2 weeks prior to the date of conception (approximately 5 half-lives), and/or plans to receive treatment with risdiplam during pregnancy.
  • Ever treated with intrathecal or intravenous onasemnogene abeparvovec.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Nusinersen Treated Participants

    Pregnant participants with SMA who are exposed to 12 or 50/28 mg nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR), Adult SMA REACH, SMArtCARE and Polish SMA Patient registry will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    Administered as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Number of Pregnancy Terminations

    Pregnancy termination is defined as any induced or voluntary fetal loss during pregnancy.

    Time frame: Up to 10 years

  2. Number of Spontaneous Abortions

    Spontaneous abortion is defined as any loss of a fetus due to natural causes at \<20 weeks of gestation.

    Time frame: Up to 10 years

  3. Number of Fetal Deaths

    Fetal deaths include early fetal loss which is fetal death occurring at ≥20 weeks but \<28 weeks of gestation and late fetal loss which is fetal death occurring at ≥28 weeks of gestation.

    Time frame: Up to 10 years

  4. Number of Live Births

    Live births include premature births which is defined as delivery at \<37 weeks of gestation, full term birth which is defined as delivery at ≥37 weeks of gestation.

    Time frame: Up to 10 years

  5. Number of Neonatal, Perinatal, and Infant Deaths

    Neonatal death is defined as death occurring in a newborn prior to 28 days after birth. Perinatal death is defined as death occurring at or after 28 days and prior to 12 weeks after birth. Infant death is defined as death occurring between 12 and 52 weeks after birth, inclusive.

    Time frame: Up to 10 years

  6. Number of Major Congenital Malformations (MCMs)

    MCMs (interchangeably referred to as congenital malformations, congenital anomalies, and birth defects) are abnormalities in structural development that are medically or cosmetically significant, are present at birth, and persist in postnatal life unless or until repaired.

    Time frame: Up to 10 years

  7. Number of Infants Small for Gestational Age Birth

    Birth weight will be classified as small for gestational age (\<10th percentile), appropriate (10th-90th percentile), or large (\>90th percentile).

    Time frame: Up to 10 years

  8. Number of Ectopic and Molar Pregnancies

    Ectopic pregnancy is defined as a pregnancy that occurs outside of the uterine cavity. Molar pregnancy is defined as genetically abnormal conceptions characterized by abnormal chorionic villi, trophoblastic hyperplasia, poor fetal development, and an increased risk of malignant disease development.

    Time frame: Up to 10 years

  9. Number of Maternal Deaths

    Maternal deaths during pregnancy, labor, delivery, or up to 12 weeks after delivery will be reported.

    Time frame: Up to 10 years

  10. Number of Infants With Abnormal Postnatal Growth and Development and Neurobehavioral Impairment

    Abnormal postnatal growth and development and neurobehavioral impairment in infants up to 24 months of age will be reported.

    Time frame: Up to 10 years

07

Study locations

13 of 14 sites recruiting
  • Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
    Recruiting
    • · Contact650-725-7622
    • John W. Day · Principal investigator
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • · Contact617-355-8036
    • Basil T. Darras · Principal investigator
  • Research Site
    Cambridge, Massachusetts 02142, United States
    Active, not recruiting

    Not enrolling at this site.

  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
    • · Contact212-305-1319
    • Michio Hirano · Principal investigator
  • University College London Hospitals NHS Foundation Trust
    London, Greater London NW1 2PG, United Kingdom
    Recruiting
    • · Contact020 3456 7890
    • Matt Parton · Principal investigator
  • St George's University NHS Foundation Trust
    London, Greater London SW17 0QT, United Kingdom
    Recruiting
    • · Contact020 8672 1255
    • Clare Galtrey · Principal investigator
  • The Northern Care Alliance NHS Foundation Trust
    Salford, Greater Manchester M6 8HD, United Kingdom
    Recruiting
    • · Contact0161 789 7373
    • James Lilleker · Principal investigator
  • University Hospital Southampton NHS Foundation Trust
    Southampton, Hampshire SO16 6YD, United Kingdom
    Recruiting
    • · Contact023 8077 7222
    • Annamaria Kiss-csenki · Principal investigator
  • Nottingham University Hospitals Trust
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
    Recruiting
    • · Contact0115 969 1169
    • Saam Sedehizadeh · Principal investigator
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
    Oswestry, Shropshire SY10 7AG, United Kingdom
    Recruiting
    • · Contact01691 404000
    • Tracey Willis · Principal investigator
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield, South Yorkshire S10 2SB, United Kingdom
    Recruiting
    • · Contact0114 271 7000
    • Channa Hewamadduma · Principal investigator
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, Tyne and Wear NE7 7ND, United Kingdom
    Recruiting
    • · Contact0191 233 6161
    • Chiara Marini-Bettolo · Principal investigator
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, West Midlands B15 2GW, United Kingdom
    Recruiting
    • · Contact(0121) 432 3232
    • Nicholas Davies · Principal investigator
  • North Bristol NHS Trust
    Bristol, BS10 5NB, United Kingdom
    Recruiting
    • · Contact0117 950 5050
    • Andria Merrison · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Oct 2032, 106 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 106 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Mar 29, 2023
StartActual
Dec 15, 2023
Primary completionEst.
Oct 31, 2032
CompletionEst.
Oct 31, 2033
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 criteria edited, 1 added
What changed in the criteria
  • EditedParticipant who is currently pregnant (or was pregnant during the relevant exposure window) and enrolled in the United States (US) network of the ISMAR registry, the United Kingdom (UK) Adult SMA REACH, or the Germany, Austria, or Switzerland network of the SMArtCARE registry, or the Polish SMA Patient registry.
  • EditedDocumentation that the participant was exposed to nusinersen 12 or 50/28 mg up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before conception, and/or at any time during their pregnancy.
  • AddedEver treated with intrathecal or intravenous onasemnogene abeparvovec.
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Eligibility 2 criteria edited, 1 added
    What changed in the criteria
    • EditedParticipant who is currently pregnant (or was pregnant during the relevant exposure window) and enrolled in the United States (US) network of the ISMAR registry, the United Kingdom (UK) Adult SMA REACH, or the Germany, Austria, or Switzerland network of the SMArtCARE registry, or the Polish SMA Patient registry.
    • EditedDocumentation that the participant was exposed to nusinersen 12 or 50/28 mg up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before conception, and/or at any time during their pregnancy.
    • AddedEver treated with intrathecal or intravenous onasemnogene abeparvovec.
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05789758
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
Dec 15, 2023
Primary completion
Oct 31, 2032 (estimated)
Completion
Oct 31, 2033 (estimated)
Last update
Nov 12, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion